336 related articles for article (PubMed ID: 29946007)
1. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
Flaherty KR; Kolb M; Vancheri C; Tang W; Conoscenti CS; Richeldi L
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946007
[TBL] [Abstract][Full Text] [Related]
2. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
[TBL] [Abstract][Full Text] [Related]
3. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
[TBL] [Abstract][Full Text] [Related]
6. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
Richeldi L; Crestani B; Azuma A; Kolb M; Selman M; Stansen W; Quaresma M; Stowasser S; Cottin V
Respir Med; 2019 Sep; 156():20-25. PubMed ID: 31404749
[TBL] [Abstract][Full Text] [Related]
7. Subgroup analysis of Asian patients in the INPULSIS
Taniguchi H; Xu Z; Azuma A; Inoue Y; Li H; Fujimoto T; Bailes Z; Schlenker-Herceg R; Kim DS
Respirology; 2016 Nov; 21(8):1425-1430. PubMed ID: 27399197
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
[TBL] [Abstract][Full Text] [Related]
9. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
Song JW; Ogura T; Inoue Y; Xu Z; Quaresma M; Stowasser S; Stansen W; Crestani B
Respirology; 2020 Apr; 25(4):410-416. PubMed ID: 31329360
[TBL] [Abstract][Full Text] [Related]
12. Subgroup Analysis for Chinese Patients Included in the INPULSIS
Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Costabel U; Inoue Y; Richeldi L; Collard HR; Tschoepe I; Stowasser S; Azuma A
Am J Respir Crit Care Med; 2016 Jan; 193(2):178-85. PubMed ID: 26393389
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Kolb M; Richeldi L; Behr J; Maher TM; Tang W; Stowasser S; Hallmann C; du Bois RM
Thorax; 2017 Apr; 72(4):340-346. PubMed ID: 27672117
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
[TBL] [Abstract][Full Text] [Related]
17. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
18. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.
Costabel U; Behr J; Crestani B; Stansen W; Schlenker-Herceg R; Stowasser S; Raghu G
Respir Res; 2018 Sep; 19(1):167. PubMed ID: 30176872
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
[TBL] [Abstract][Full Text] [Related]
20. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.
Kreuter M; Costabel U; Richeldi L; Cottin V; Wijsenbeek M; Bonella F; Bendstrup E; Maher TM; Wachtlin D; Stowasser S; Kolb M
Respiration; 2018; 95(5):317-326. PubMed ID: 29414827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
